



RNS Number : 8190Q
Roquefort Therapeutics PLC
30 June 2022

30 June 2022

Roquefort Therapeutics plc
("Roquefort Therapeutics" or the "Company")

Results of AGM

Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company focused on early-stage opportunities in the biotechnology sector, is pleased to announce that at the Company's Annual General Meeting ("**AGM**") held earlier today, all resolutions proposed were duly passed.

The resolutions were put to shareholders via a poll, the results of which were as follows:

Resolution		Poll Results				
		For	Against	Abstain	Discretionary	Total
1	Shares	15,398,450	-	-	1,600,000	16,998,450
	%	90.59%	-	-	9.41%	100%
2	Shares	15,398,450	-	-	1,600,000	16,998,450
	%	90.59%	-	-	9.41%	100%
3	Shares	15,398,450	-	-	1,600,000	16,998,450
	%	90.59%	-	-	9.41%	100%
4	Shares	15,398,450	-	-	1,600,000	16,998,450
	%	90.59%	-	-	9.41%	100%
5	Shares	15,363,384	35,066	-	1,600,000	16,998,450
	%	90.38%	0.21%	-	9.41%	100%
6	Shares	15,398,450	-	-	1,600,000	16,998,450
	%	90.59%	-	-	9.41%	100%
7	Shares	15,398,450	-	-	1,600,000	16,998,450
	%	90.59%	-	-	9.41%	100%
8	Shares	15,398,450	-	-	1,600,000	16,998,450
	%	90.59%	-	-	9.41%	100%
9	Shares	15,363,384	35,066	-	1,600,000	16,998,450
	%	90.38%	0.21%	-	9.41%	100%
10	Shares	15,363,384	35,066	-	1,600,000	16,998,450
	%	90.38%	0.21%	-	9.41%	100%

The total number of ordinary shares in issue on 28 June 2022, the deadline for casting votes by proxy in advance of the AGM, was 71,900,000 shares. 23.64% of voting capital was instructed in respect of the resolutions put to the AGM.

Enquiries:

Roquefort Therapeutics plc

Stephen West (Chairman) +44 (0)20 3290
9339

Buchanan (Public Relations)

Ben Romney / Jamie Hooper / George Beale +44 (0)20 7466
5000

Optiva Securities Limited (Broker)

Christian Dennis +44 (0)20 3411
1881

For further information on Roquefort Therapeutics, please visit www.roquefortplc.com
and @RoquefortTherap on Twitter.

LEI: 254900P4SISIWOR9RH34

About Roquefort Therapeutics

Roquefort Therapeutics (LSE:ROQ) is a Main Market listed biotech company developing products through the pre-clinical phase prior to partnering or selling to big pharma. The Company is a pre-clinical biotech company focused on developing first in class Midkine targeting drugs for the treatment of cancer.

Through extensive research resulting in validation through publication in over 1,000 scientific journals, Roquefort Therapeutics has identified the potential to exploit the broad therapeutic potential of Midkine for a number of clinical indications of unmet needs. Roquefort Therapeutics holds an exclusive licence to the largest global IP portfolio on Midkine. The Midkine blocking drug development markets have significant global market potential (in the multi-billion dollars). Roquefort Therapeutic's pre-clinical program is currently underway with an initial focus on cancer.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

RAGSDDSUSEEFM

Anonymous (not verified)

Result of AGM

32788101

A

Thu, 06/30/2022 - 10:30

LSE RNS

Results and Trading Reports

ROQ